

Particulars	CONSOLIDATED					
	Quarter Ended			Nine Months		Year Ended
	December-12	September-12	December-11	December-12	December-11	March-12
	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
<b>PART- I</b>						
<b>1 (a) Net Sales / Income from Operations</b>						
Domestic	25,470	28,913	21,766	77,253	67,391	87,718
Exports	11,735	11,840	16,516	37,511	45,168	59,071
Total	37,205	40,753	38,282	114,764	112,559	146,789
Less : Excise Duty	325	173	149	697	403	554
Net Sales / Income from Operations	36,880	40,580	38,133	114,067	112,156	146,235
<b>(b) Other Operating Income</b>	48	105	79	223	222	404
<b>Total Income from Operations</b>	<b>36,928</b>	<b>40,685</b>	<b>38,212</b>	<b>114,290</b>	<b>112,378</b>	<b>146,639</b>
<b>2 Expenses</b>						
(a) Decrease/(increase) in stock in trade and work in progress	(2,223)	1,949	250	(416)	(3,009)	(6,444)
(b) Consumption of Raw Materials & Packing Materials	12,420	12,631	12,916	36,220	40,140	52,824
(c) Purchase of traded goods	4,866	4,277	5,774	15,558	18,357	24,412
(d) Employees' Cost	4,952	4,855	4,324	14,302	12,535	16,846
(e) Research and Development Expense	2,172	1,603	976	5,163	3,645	5,858
(f) Excise Duty	(302)	117	(37)	(71)	198	509
(g) Other Expenditure	8,103	8,783	7,161	24,896	22,582	30,593
<b>Total Expenses</b>	<b>29,988</b>	<b>34,215</b>	<b>31,364</b>	<b>95,652</b>	<b>94,448</b>	<b>124,597</b>
<b>3 Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>6,940</b>	<b>6,470</b>	<b>6,848</b>	<b>18,638</b>	<b>17,930</b>	<b>22,041</b>
<b>4 Other Income</b>	<b>342</b>	<b>22</b>	<b>13</b>	<b>386</b>	<b>31</b>	<b>44</b>
<b>5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>7,282</b>	<b>6,492</b>	<b>6,861</b>	<b>19,024</b>	<b>17,961</b>	<b>22,086</b>
<b>6 Depreciation</b>	<b>885</b>	<b>882</b>	<b>809</b>	<b>2,633</b>	<b>2,473</b>	<b>3,365</b>
<b>7 Interest (Net)</b>	<b>388</b>	<b>312</b>	<b>698</b>	<b>1,274</b>	<b>2,083</b>	<b>2,621</b>
<b>8 Net Profit / (Loss) from Ordinary Activities before Tax</b>	<b>6,009</b>	<b>5,298</b>	<b>5,354</b>	<b>15,117</b>	<b>13,405</b>	<b>16,099</b>
<b>9 Tax Expense</b>						
Less : Provision for Current Tax	1,211	1,055	964	2,997	2,597	3,123
Less/(Add) : Provision for Deferred Tax Liability /(Assets)	(29)	(6)	(33)	(40)	(175)	(38)
<b>10 Net Profit / (Loss) from Ordinary Activities after Tax</b>	<b>4,827</b>	<b>4,249</b>	<b>4,423</b>	<b>12,160</b>	<b>10,983</b>	<b>13,014</b>
<b>11 Paid up Equity Share Capital</b> ( Face value of share ` 2/- )	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>
<b>12 Reserves excluding Revaluation Reserve</b>	-	-	-	-	-	<b>35,730</b>
<b>13 Debenture Redemption Reserve</b>	-	-	-	-	-	<b>3,125</b>
<b>14 Basic &amp; Diluted EPS (Not Annualised)</b>	<b>2.56</b>	<b>2.25</b>	<b>2.35</b>	<b>6.45</b>	<b>5.83</b>	<b>6.90</b>
<b>PART- II</b>						
<b>A Particulars of Shareholding</b>						
<b>1 Public Shareholding</b>						
- Number of Shares	48777294	48777294	48763089	48777294	48763089	48763089
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
<b>2 Promoters and Promoter Group Shareholding</b>						
- Fully Non - Encumbered						
- Number of Shares	139738620	139738620	139752825	139738620	139752825	139752825
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
<b>B INVESTOR COMPLAINTS</b>	<b>Quarter ended on 31st December, 2012</b>					
Pending at the beginning of the quarter	NIL					
Received during the quarter	1					
Disposed of during the quarter	1					
Remaining unresolved at the end of the quarter	NIL					

Particulars	STANDALONE						
	Quarter Ended			Nine Months		Year Ended	
	December-12	September-12	December-11	December-12	December-11	March-12	
	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)	
<b>PART- I</b>							
<b>1 (a) Net Sales / Income from Operations</b>							
Domestic	25,470	28,913	21,766	77,253	67,391	87,718	
Exports	11,735	11,840	13,294	34,775	38,461	49,961	
Total	37,205	40,753	35,060	112,028	105,852	137,679	
Less : Excise Duty	325	173	149	697	403	554	
Net Sales / Income from Operations	36,880	40,580	34,911	111,331	105,449	137,125	
<b>(b) Other Operating Income</b>	48	105	79	223	222	404	
<b>Total Income from Operations</b>	<b>36,928</b>	<b>40,685</b>	<b>34,990</b>	<b>111,553</b>	<b>105,671</b>	<b>137,528</b>	
<b>2 Expenses</b>							
(a) Decrease/(increase) in stock in trade and work in progress	(2,223)	1,949	250	(416)	(3,009)	(6,444)	
(b) Consumption of Raw Materials & Packing Materials	12,420	12,631	12,916	36,220	40,140	52,824	
(c) Purchase of traded goods	4,866	4,277	3,272	13,211	12,669	16,779	
(d) Employees' Cost	4,952	4,855	4,324	14,302	12,535	16,846	
(e) Research and Development Expense	2,172	1,603	976	5,163	3,645	5,858	
(f) Excise Duty	(302)	117	(37)	(71)	198	509	
(g) Other Expenditure	8,019	8,898	7,263	24,939	22,487	30,200	
<b>Total Expenses</b>	<b>29,904</b>	<b>34,330</b>	<b>28,964</b>	<b>93,347</b>	<b>88,665</b>	<b>116,571</b>	
<b>3 Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>7,024</b>	<b>6,355</b>	<b>6,026</b>	<b>18,206</b>	<b>17,006</b>	<b>20,957</b>	
<b>4 Other Income</b>	<b>342</b>	<b>22</b>	<b>13</b>	<b>386</b>	<b>31</b>	<b>44</b>	
<b>5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>7,366</b>	<b>6,377</b>	<b>6,039</b>	<b>18,592</b>	<b>17,037</b>	<b>21,001</b>	
<b>6 Depreciation</b>	<b>885</b>	<b>882</b>	<b>809</b>	<b>2,632</b>	<b>2,473</b>	<b>3,365</b>	
<b>7 Interest (Net)</b>	<b>388</b>	<b>312</b>	<b>698</b>	<b>1,274</b>	<b>2,083</b>	<b>2,621</b>	
<b>8 Net Profit / (Loss) from Ordinary Activities before Tax</b>	<b>6,093</b>	<b>5,183</b>	<b>4,532</b>	<b>14,686</b>	<b>12,481</b>	<b>15,015</b>	
<b>9 Tax Expense</b>							
Less : Provision for Current Tax	1,222	1,042	864	2,951	2,492	3,000	
Less /Add : Provision for Deferred Tax Liability/(Assets)	(29)	(6)	(33)	(40)	(175)	(38)	
<b>10 Net Profit / (Loss) from Ordinary Activities after Tax</b>	<b>4,900</b>	<b>4,147</b>	<b>3,701</b>	<b>11,775</b>	<b>10,164</b>	<b>12,054</b>	
<b>11 Paid up Equity Share Capital</b> ( Face value of share ` 2/- )	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	
<b>12 Reserves excluding Revaluation Reserve</b>	-	-	-	-	-	<b>32,316</b>	
<b>13 Debenture Redemption Reserve</b>	-	-	-	-	-	<b>3,125</b>	
<b>14 Basic &amp; Diluted EPS (Not Annualised)</b>	<b>2.60</b>	<b>2.20</b>	<b>1.96</b>	<b>6.25</b>	<b>5.39</b>	<b>6.39</b>	
<b>PART- II</b>							
<b>A Particulars of Shareholding</b>							
<b>1 Public Shareholding</b>							
- Number of Shares	48777294	48777294	48763089	48777294	48763089	48763089	
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87	
<b>2 Promoters and Promoter Group Shareholding</b>							
- Fully Non - Encumbered							
- Number of Shares	139738620	139738620	139752825	139738620	139752825	139752825	
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13	
<b>B INVESTOR COMPLAINTS</b>							
	<b>Quarter ended on 31st December, 2012</b>						
Pending at the beginning of the quarter	NIL						
Received during the quarter	1						
Disposed of during the quarter	1						
Remaining unresolved at the end of the quarter	NIL						

**Notes :**

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website [www.alembic-india.com](http://www.alembic-india.com).
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

**For Alembic Pharmaceuticals Limited**

Place : Vadodara

Date : 21st January 2013

**Chirayu Amin**

**Chairman and Managing Director**

**Visit us at [www.alembic-india.com](http://www.alembic-india.com)**